Key result
Adjunct L-arginine supplement reduces macrovascular endothelial dysfunction by ~47 percentage points in hypertensive CRMS.
Why the study?
Endothelial dysfunction plays a key role in cardio-renal-metabolic syndrome, and persistent residual cardiovascular risk despite control of traditional risk factors warrants additional therapeutic approaches.
Does a multi-action dietary supplement containing L-arginine, succinic acid, and L-carnitine tartrate improve endothelial function, platelet aggregation, and heart rate variability in patients with grade 2 stage 2 hypertension and cardio-renal-metabolic syndrome?
Does a multi-action dietary supplement containing L-arginine, succinic acid, and L-carnitine tartrate improve endothelial function, platelet aggregation, and heart rate variability in patients with grade 2 stage 2 hypertension and cardio-renal-metabolic syndrome?
Adjunct therapy with an L-arginine, succinic acid, and L-carnitine dietary supplement was associated with significant improvements in macrovascular and microvascular endothelial function, blood pressure, and autonomic regulation over 1 month in patients with hypertension and cardio-renal-metabolic syndrome.
Answers are grounded in this paper and cite their sources.
May improve endothelial function in hypertension with CRMS; hypothesis-generating and requires randomized confirmation before practice change.
А key role in сardio-renal-metabolic syndrome (CRMS) is endothelial dysfunction (ED). Persistent residual cardiovascular risk despite control of traditional risk factors warrants additional therapeutic approaches.The objective: to evaluate the effects of a multi-action dietary supplement (DS) (L-arginine 2,240 mg, succinic acid 760 mg, L-carnitine tartrate 500 mg) on endothelial function (EF), platelet aggregation, and heart rate variability in patients with grade 2 stage 2 hypertension and CRMS features.Materials and methods. 32 patients (55.22 ± 1.85 years) receiving standard antihypertensive and statin therapy were assessed. Anthropometric, hemodynamic, and biochemical parameters, EF status, microcirculation, platelet aggregation, and heart rate variability were analyzed before and after 1 month of DS therapy.Results. Macrovascular ED was detected in 62.5%, microvascular ED – in 87.5% of patients. ED was associated with higher body mass index, lower high-density lipoprotein cholesterol, an atherogenic lipid profile and increased platelet reactivity. After therapy, the rate of macrovascular ED decreased from 62.5% to 15.6% (p < 0.001), flow-mediated dilation increased from 3.75 ± 0.77% to 20.60 ± 4.19% (p < 0.01), and microvascular EF – from 67.37 ± 6.05% to 86.70 ± 6.26% (p < 0.05). Microcirculatory and hemorheological parameters improved, systolic and diastolic blood pressure decreased, and heart rate variability showed reduced very low-frequency and increased high-frequency components.Conclusions. The use of a multi-action DS as an adjunct therapy was associated with improved EF, microcirculation, hemorheology, and autonomic cardiovascular regulation, as well as reduction of blood pressure. These findings justify further study of this approach as a component of comprehensive management in patients with CRMS.
No takes yet. Share an insight, caveat, or question.
Chizhova et al. (2026) studied Grade 2 stage 2 hypertension and cardio-renal-metabolic syndrome (CRMS) (n=32). Multi-action dietary supplement (L-arginine, succinic acid, L-carnitine tartrate) vs. Baseline (pre-treatment values on standard antihypertensive and statin therapy) was evaluated on Rate of macrovascular endothelial dysfunction (p=<0.001). Adjunct L-arginine-containing dietary supplement therapy for 1 month reduced macrovascular endothelial dysfunction from 62.5% to 15.6% in patients with hypertension and CRMS.
Synapse has enriched 10 related papers. Consider them for comparative context: